Neuromelanin magnetic resonance imaging of the substantia nigra in LRRK2-related Parkinson's disease

Mov Disord. 2017 Sep;32(9):1331-1333. doi: 10.1002/mds.27083. Epub 2017 Jul 7.

Leonor Correia Guedes^{1

2}, Sofia Reimão^{2

3}, Patrícia Paulino^{4

5}, Rita G Nunes⁴, Raquel Bouça-Machado², Daisy Abreu², Nilza Gonçalves², Tiago Soares², Margherita Fabbri², Catarina Godinho², Patrícia Pita Lobo², Dulce Neutel², Marialuisa Quadri⁶, Miguel Coelho^{1

2}, Mario M Rosa^{1

2

7}, Jorge Campos³, Tiago F Outeiro^{8

9

10}, Cristina Sampaio⁷, Vincenzo Bonifati⁶, Joaquim J Ferreira^{2

7

11}

¹ Department of Neurosciences and Mental Health, Neurology, Hospital de Santa Maria-CHLN, Lisbon, Portugal.
² Clinical Pharmachology Unit, Instituto de Medicina Molecular, Lisbon, Portugal.
³ Neurological Imaging Department, Hospital de Santa Maria-CHLN, Lisbon, Portugal.
⁴ Instituto de Biofísica e Engenharia Biomédica, Faculty of Science, University of Lisbon, Portugal.
⁵ Faculty of Science and Technology, Nova University of Lisbon, Campus da Caparica, Portugal.
⁶ Department of Clinical Genetics, Erasmus MC, Rotterdam, The Netherlands.
⁷ Laboratory of Clinical Pharmachology and Therapeutics, Faculty of Medicine, University of Lisbon, Portugal.
⁸ CEDOC, Chronic Diseases Research Centre, Nova Medical School, Nova University of Lisbon, Lisboa, Portugal.
⁹ Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, Center for Nanoscale Microscopy and Molecular Physiology of the Brain (CNMPB), University Medical Center Gottingen, Germany.
¹⁰ Max Planck Institute for Experimental Medicine, Gottingen, Germany.
¹¹ CNS-Campus Neurológico Sénior, Torres Vedras, Portugal.

No abstract available

Publication types